Literature DB >> 22993410

Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera.

Russell A Johnson1, Taher Uddin, Amena Aktar, M Mohasin, Mohammad Murshid Alam, Fahima Chowdhury, Jason B Harris, Regina C LaRocque, Meagan Kelly Bufano, Yanan Yu, Ying Wu-Freeman, Daniel T Leung, David Sarracino, Bryan Krastins, Richelle C Charles, Peng Xu, Pavol Kovác, Stephen B Calderwood, Firdausi Qadri, Edward T Ryan.   

Abstract

Immunity against Vibrio cholerae O1 is serogroup specific, and serogrouping is defined by the O-specific polysaccharide (OSP) part of lipopolysaccharide (LPS). Despite this, human immune responses to V. cholerae OSP have not previously been characterized. We assessed immune responses against V. cholerae OSP in adults with cholera caused by V. cholerae O1 El Tor serotype Inaba or Ogawa in Dhaka, Bangladesh, using O1 OSP-core-bovine serum albumin (OSPc:BSA) conjugates; responses targeted OSP in these conjugates. Responses of Inaba-infected patients to Inaba OSP and LPS increased significantly in IgG, IgM, and IgA isotypes from the acute to convalescent phases of illness, and the responses correlated well between OSP and LPS (R = 0.86, 0.73, and 0.91, respectively; P < 0.01). Plasma IgG, IgM, and IgA responses to Ogawa OSP and LPS in Ogawa-infected patients also correlated well with each other (R = 0.60, 0.60, and 0.92, respectively; P < 0.01). Plasma IgM responses to Inaba OSP and Ogawa OSP correlated with the respective serogroup-specific vibriocidal antibodies (R = 0.80 and 0.66, respectively; P < 0.001). Addition of either OSPc:BSA or LPS, but not BSA, to vibriocidal assays inhibited vibriocidal responses in a comparable and concentration-dependent manner. Mucosal IgA immune responses to OSP and LPS were also similar. Our study is the first to characterize anti-OSP immune responses in patients with cholera and suggests that responses targeting V. cholerae LPS, including vibriocidal responses that correlate with protection against cholera, predominantly target OSP. Induction of anti-OSP responses may be associated with protection against cholera, and our results may support the development of a vaccine targeting V. cholerae OSP.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22993410      PMCID: PMC3491541          DOI: 10.1128/CVI.00321-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  52 in total

1.  Mass spectrometric discovery and selective reaction monitoring (SRM) of putative protein biomarker candidates in first trimester Trisomy 21 maternal serum.

Authors:  Mary F Lopez; Ramesh Kuppusamy; David A Sarracino; Amol Prakash; Michael Athanas; Bryan Krastins; Taha Rezai; Jennifer N Sutton; Scott Peterman; Kypros Nicolaides
Journal:  J Proteome Res       Date:  2010-06-04       Impact factor: 4.466

2.  The 1968-1969 cholera-vaccine field trial in rural East Pakistan. Effectiveness of monovalent Ogawa and Inaba vaccines and a purified Inaba antigen, with comparative results of serological and animal protection tests.

Authors:  W H Mosley; W E Woodward; K M Aziz; A S Rahman; A K Chowdhury; A Ahmed; J C Feeley
Journal:  J Infect Dis       Date:  1970-05       Impact factor: 5.226

3.  Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection.

Authors:  R I Glass; A M Svennerholm; M R Khan; S Huda; M I Huq; J Holmgren
Journal:  J Infect Dis       Date:  1985-02       Impact factor: 5.226

4.  Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine.

Authors:  A M Svennerholm; M Jertborn; L Gothefors; A M Karim; D A Sack; J Holmgren
Journal:  J Infect Dis       Date:  1984-06       Impact factor: 5.226

5.  The antigens of Vibrio cholerae involved in the vibriocidal action of antibody and complement.

Authors:  S H Neoh; D Rowley
Journal:  J Infect Dis       Date:  1970-05       Impact factor: 5.226

6.  Duration of infection-derived immunity to cholera.

Authors:  M M Levine; R E Black; M L Clements; L Cisneros; D R Nalin; C R Young
Journal:  J Infect Dis       Date:  1981-06       Impact factor: 5.226

7.  IgA antibody-producing cells in peripheral blood after antigen ingestion: evidence for a common mucosal immune system in humans.

Authors:  C Czerkinsky; S J Prince; S M Michalek; S Jackson; M W Russell; Z Moldoveanu; J R McGhee; J Mestecky
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

8.  Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers.

Authors:  Firdausi Qadri; Edward T Ryan; A S G Faruque; Firoz Ahmed; Ashraful Islam Khan; M Monirul Islam; Syed M Akramuzzaman; David A Sack; Stephen B Calderwood
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

9.  Field trials of monovalent Ogawa and Inaba cholera vaccines in rural Bangladesh--three years of observation.

Authors:  W H Mosley; K M Aziz; A S Rahman; A K Chowdhury; A Ahmed
Journal:  Bull World Health Organ       Date:  1973       Impact factor: 9.408

10.  Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. 2. Results of the serological surveys in the study population--the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae.

Authors:  W H Mosley; W M McCormack; A Ahmed; A K Chowdhury; R K Barui
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

View more
  45 in total

1.  Rapid effects of a protective O-polysaccharide-specific monoclonal IgA on Vibrio cholerae agglutination, motility, and surface morphology.

Authors:  Kara J Levinson; Magdia De Jesus; Nicholas J Mantis
Journal:  Infect Immun       Date:  2015-02-09       Impact factor: 3.441

Review 2.  Use of Pathogen-Specific Antibody Biomarkers to Estimate Waterborne Infections in Population-Based Settings.

Authors:  Natalie G Exum; Nora Pisanic; Douglas A Granger; Kellogg J Schwab; Barbara Detrick; Margaret Kosek; Andrey I Egorov; Shannon M Griffin; Christopher D Heaney
Journal:  Curr Environ Health Rep       Date:  2016-09

3.  Insights from natural infection-derived immunity to cholera instruct vaccine efforts.

Authors:  Marcela F Pasetti; Myron M Levine
Journal:  Clin Vaccine Immunol       Date:  2012-09-19

4.  Enumeration of Gut-Homing β7-Positive, Pathogen-Specific Antibody-Secreting Cells in Whole Blood from Enterotoxigenic Escherichia coli- and Vibrio cholerae-Infected Patients, Determined Using an Enzyme-Linked Immunosorbent Spot Assay Technique.

Authors:  Taufiqur Rahman Bhuiyan; Mohammad Rubel Hoq; Naoshin Sharmin Nishat; Deena Al Mahbuba; Rasheduzzaman Rashu; Kamrul Islam; Lazina Hossain; Ayan Dey; Jason B Harris; Edward T Ryan; Stephen B Calderwood; Ann-Mari Svennerholm; Firdausi Qadri
Journal:  Clin Vaccine Immunol       Date:  2015-10-28

5.  Immune responses to O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 Ogawa in adult Bangladeshi recipients of an oral killed cholera vaccine and comparison to responses in patients with cholera.

Authors:  Taher Uddin; Amena Aktar; Peng Xu; Russell A Johnson; M Arifur Rahman; Daniel T Leung; Sadia Afrin; Aklima Akter; Mohammad Murshid Alam; Atiqur Rahman; Fahima Chowdhury; Ashraful I Khan; Taufiqur Rahman Bhuiyan; Meagan K Bufano; Rasheduzzaman Rashu; Yanan Yu; Ying Wu-Freeman; Jason B Harris; Regina C LaRocque; Richelle C Charles; Pavol Kováč; Stephen B Calderwood; Edward T Ryan; Firdausi Qadri
Journal:  Am J Trop Med Hyg       Date:  2014-03-31       Impact factor: 2.345

Review 6.  Nutritional Modulation of the Microbiome and Immune Response.

Authors:  Ansen H P Burr; Amrita Bhattacharjee; Timothy W Hand
Journal:  J Immunol       Date:  2020-09-15       Impact factor: 5.422

7.  Plant-based production of two chimeric monoclonal IgG antibodies directed against immunodominant epitopes of Vibrio cholerae lipopolysaccharide.

Authors:  Kara J Levinson; Samantha R Giffen; Michael H Pauly; Do H Kim; Ognian Bohorov; Natasha Bohorova; Kevin J Whaley; Larry Zeitlin; Nicholas J Mantis
Journal:  J Immunol Methods       Date:  2015-04-09       Impact factor: 2.303

8.  Transcriptional profiling of Vibrio cholerae O1 following exposure to human anti- lipopolysaccharide monoclonal antibodies.

Authors:  Danielle E Baranova; Graham G Willsey; Kara J Levinson; Carol Smith; Joseph Wade; Nicholas J Mantis
Journal:  Pathog Dis       Date:  2020-06-01       Impact factor: 3.166

9.  Lipopolysaccharide modifications of a cholera vaccine candidate based on outer membrane vesicles reduce endotoxicity and reveal the major protective antigen.

Authors:  Deborah R Leitner; Sandra Feichter; Kristina Schild-Prüfert; Gerald N Rechberger; Joachim Reidl; Stefan Schild
Journal:  Infect Immun       Date:  2013-04-29       Impact factor: 3.441

10.  O-Specific Polysaccharide-Specific Memory B Cell Responses in Young Children, Older Children, and Adults Infected with Vibrio cholerae O1 Ogawa in Bangladesh.

Authors:  Amena Aktar; M Arifur Rahman; Sadia Afrin; M Omar Faruk; Taher Uddin; Aklima Akter; M Israk Nur Sami; Tahirah Yasmin; Fahima Chowdhury; Ashraful I Khan; Daniel T Leung; Regina C LaRocque; Richelle C Charles; Taufiqur Rahman Bhuiyan; Anjali Mandlik; Meagan Kelly; Pavol Kováč; Peng Xu; Stephen B Calderwood; Jason B Harris; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2016-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.